Cytokinetics is dedicated to the discovery, development and commercialization of novel therapeutics within the emerging field of cytoskeletal pharmacology. The cytoskeleton is a complex, dynamic framework that impacts all aspects of cell function including division, motility, transport, muscle contractility and cellular organization. Cytokinetics' R&D efforts aim to address pharmaceutical needs in cancer, cardiovascular and infectious diseases and feature proprietary Cytometrix™ cellular phenotyping technologies designed to industrialize cell biology for increased speed and productivity in drug discovery and development. Cytokinetics and GlaxoSmithKline have begun Phase I studies with the first novel anti-cancer drug candidate under their collaboration. The company is building a promising pipeline of next-generation drug candidates arising from other internal pharmaceutical research programs and is planning the initiation of clinical studies for other potential first-in-class compounds.

Cytokinetics' mission is to translate the power of cell biology into novel pharmaceuticals and technologies with the objective to enhance patient care.